Reimagining Methadone Clinics: A Case For Integrating Risk Reduction to Address the Complex Realities of Opioid Use Disorder

Introduction

Emerging in the 1960s as a therapeutic modality, methadone remains one of the gold standard treatments for opioid use disorder (OUD), alleviating withdrawal symptoms, curbing cravings, and decreasing OUD-related morbidity and mortality. Despite this, methadone delivery in the United States remains highly siloed and tightly regulated, with some treatment programs enforcing punitive rather than patient-centered treatment approaches. ¹

Regulations by the Food and Drug Administration and Drug Enforcement Administration in 1972 restricted methadone for OUD treatment to federally approved clinics called opioid treatment programs (OTPs). ² Additional policies shape patient treatment plans, including methadone initiation doses, urine drug screening frequency, counseling needs, and supervised dosing requirements. Despite decades of evidence supporting methadone as safe and effective, these policies have remained largely unchanged until recent updates in 2024, when the Substance Abuse and Mental Health Services Administration (SAMHSA) introduced regulatory updates that modestly eased requirements around treatment eligibility, telehealth use, dosing, take-home privileges, and methadone access at select non-OTP facilities. ³ While these are important initial steps toward deregulating methadone, the evolving opioid crisis which is marked by highly potent synthetic opioids, adulterants, and widespread polysubstance use, calls for more comprehensive approaches.

In this context of ongoing methadone regulatory changes, OTPs have a unique opportunity to integrate evidence-informed risk reduction strategies that address persistent systemic challenges in methadone delivery under current federal and state policies and may reduce risks related to the unregulated drug supply, polysubstance use, co-occurring psychiatric conditions, and limited social support.^4-8 With their existing clinical infrastructure, OTPs are well positioned to deliver services such as naloxone distribution and safer use supplies, aligning with recent public health priorities and federal investments. ⁹ Methadone and risk reduction services are rarely delivered together in US healthcare, highlighting the need for exploratory implementation to assess the feasibility of such integrated approaches.

Risk reduction integration has been described in other healthcare settings including inpatient and office-based addiction treatment environments as a feasible and acceptable intervention, complementing traditional addiction treatment processes and supporting patients’ healthcare needs.^10,11 We describe the implementation process and early uptake of a pragmatic pilot program to integrate safer use kit distribution in an urban OTP to demonstrate patient and provider interest in concurrent delivery strategies. This report provides a framework for future exploratory implementations of OTP risk reduction initiatives with an aim to promote continuity of care, reduce preventable harms, and increase access to life-saving services.

Methods

We implemented a pilot risk reduction program at an OTP in Western Pennsylvania that offers integrated psychiatric and substance use treatment. The program serves approximately 500 patients, averaging 215 new patients yearly, and is staffed by clinical therapists and staff members. The patient population is approximately 50% male, 80% white, and 18% Black.

Building on our previously published risk reduction implementation model in an office-based addiction treatment clinic, ¹⁰ we collaborated with 2 site administrators and 1 clinician to adapt a clinical workflow, train staff, install patient-facing signage on kit availability and sharps disposal, manage site inventory and storage, and coordinate syringe prescriptions with a local pharmacy. All patient-facing staff received standardized orientation on kit types, storage, and distribution procedures prior to program launch. Safer use kits included discreetly packaged supplies for safer injection, smoking, snorting, boofing or per rectal administration, fentanyl test strips, xylazine test strips, medetomidine test strips (which became available July 2025), wound care and were funded through the clinic operating budget. Kits were offered universally to all OTP patients without eligibility restrictions; patients could select up to one of each kit type per visit from their peer recovery specialist, a limit set to manage inventory, and assess initial demand during this pilot period. Patients were informed of kit availability through clinic signage and peer recovery specialist outreach during routine encounters; clinical therapists also facilitated kit conversations during scheduled therapy sessions. Patients could receive kits through multiple visits, though encounters were not linked longitudinally. For safer injection kits, patients also had the option to fill a syringe prescription at a local pharmacy.

We tracked volume of kit distribution over a thirteen-month period (November 2024-November 2025) by kit type using REDCap to assess feasibility and adoption of the program among OTP participants. We did not include naloxone as this was already distributed regularly prior to the pilot. All kits included instructions for use. Safer injection kits contained alcohol wipes, ascorbic acid, cookers, cotton filters, a sharps container, sterile saline ampoules, tourniquets, and twist ties. Smoking kits contained alcohol wipes, screens, lip balm, a wooden push stick, and mouthpieces. Snorting kits contained multicolored plastic straws, a plastic razor, alcohol wipes, scoops, and a blank card. Boofing kits contained lubricant, sterile saline, cookers, and rectal syringes. Wound care kits contained bandages, burn gel, gauze, antiseptic wipes, antibiotic ointment, and gloves. Test strip kits contained fentanyl, xylazine, or medetomidine test strips, scoops, cookers, and sterile water. We also collected written reflections from 3 key patient-facing staff involved in the pilot program on their experiences and the importance of kit distribution (“Do you have any personal or clinical anecdotes related to kit distribution at the clinic? From a provider perspective, why was the implementation of the kit project important for patients?”). Using a descriptive qualitative approach, we analyzed the written responses and selected illustrative quotes that highlighted key perspectives across staff roles. This pilot was approved by our institution’s Quality Review Committee.

Results

Over 13 months, the OTP distributed 643 kits during 266 encounters for 142 unique individuals, approximately one quarter of the OTP patient population, averaging 2.1 (range 1-10) kits per encounter. While there was month-to-month variation of kit distribution, on average, the OTP distributed 49.5 kits monthly (Figure 1). The most popular kits included xylazine test strips (N = 130, 20%), fentanyl test strips (N = 112, 17%), crack cocaine smoking kits (N = 84, 13%), wound care kits (N = 78, 12%), and snorting kits (11%). The site additionally distributed 67 injection kits (10%), 54 medetomidine test strip kits (8%), 34 methamphetamine smoking kits (5%), and 12 boofing kits (2%) (Figure 1).

OPEN IN VIEWER

Figure 1.

Monthly distribution of safer use kits, November 2024 to November 2025.

Overall, staff viewed the kit distribution pilot as addressing a high-priority patient need at the OTP, without perceiving any increased or prolonged substance use associated with kit access. One clinician stated:

I think access is the biggest thing, because even still, there are people I interact with at the clinic who, they know about syringe service programs, they’re aware of them, but they never go to them, because they just can’t get there and back and everything. I have never seen instances where people having the ability to access safer consumption supplies or medications that are helpful, encourage their drug use or keep it going longer. I think that’s not the reality of what’s going through people’s heads, and not the reality of what’s actually happening down on the streets.

Staff felt that the kits were synergistic with existing methadone workflows and helped strengthen therapeutic relationships by facilitating more open, nonjudgmental discussions about ongoing drug use. The clinic’s case manager noted:

I think it really benefited clients, not only because they were getting those materials and they were testing their drugs, but it caused them to have more conversations about testing their drugs. It caused them to have more conversations about literally everything. I think that the [pilot] program that we have is opening people more up. Which could further down the line get somebody thinking about reducing their use. Or stopping their use. Or being, you know, being safer to the point where they’re more functional.

Another staff member expressed similar sentiments:

Harm reduction at [this clinic] has been a bridge to clients who may be struggling or cutting back their use. It has helped build relationships with those clients who may not otherwise be engaged in treatment and helps open the door to connection with other needed resources. The harm reduction program expands our inclusivity to clients who aren’t ready to fully commit to abstinence and lets them know they are welcome and valued no matter where they are in their recovery.

Though the effect of kit distribution on clinical outcomes was not formally measured, staff noted that the kit-related discussions anecdotally opened avenues for deeper therapeutic engagement.

Discussion

Overall, we found that kit distribution was feasible and demonstrated consistent uptake at a single OTP, underscoring that individuals seek tools to reduce their health risks through available safer use supplies, even during engagement in an OTP. Several factors may explain the uptake of kits. First, patients may engage in ongoing substance use as their methadone doses are gradually titrated to therapeutic levels with starting doses and titration schedules influenced by federal, state, and OTP policies that may not necessarily reflect the physiological need for higher doses in the fentanyl era. ¹²

In addition, adulterants such as xylazine and medetomidine, alpha-2 veterinary sedatives with significant prevalence in Pennsylvania, may further complicate treatment, as methadone does not address alpha-2-associated withdrawal symptoms. The high uptake of safer smoking kits for crack cocaine and methamphetamine likely reflects the increasing prevalence of stimulant co-use among individuals with OUD. ¹³ Because OTPs may not routinely address stimulant-related risks, providing safer smoking supplies could be a clinically valuable and relevant addition within this venue.

Variability in kit distribution over time may reflect shifting drug use patterns, underscoring the need for responsive efforts to meet patient needs and the changing drug supply as demonstrated by the addition of medetomidine test strips halfway through our pilot program. Structural barriers inherent to OTPs such as inflexible dosing schedules, strict compliance requirements, and stigmatization are well-documented contributors to subsequent discontinuation of methadone treatment.^12,14,15 It is possible that providing risk reduction tools can signal support for patient autonomy within the constraints of traditional OTP settings. These approaches are particularly important for patients facing structural vulnerabilities, including housing instability, transportation barriers, and limited healthcare access. ¹⁶ While limited, staff perspectives suggest that kit distribution may help build trust and support engagement in treatment, which could support downstream retention, sustained engagement in treatment. Retention, safety outcomes, and cost were not directly measured in this pilot and remain importance targets for future research.

This pilot has several limitations that may affect generalizability and scalability. First, implementation of this proof of concept occurred in a single OTP, which may not reflect the organizational, regulatory, or patient population contexts of other settings, and additional research is needed to fully understand implementation determinants of similar integrated programs. Second, safer use kits distribution is subject to state drug paraphernalia laws, which differ substantially across jurisdictions. Compliance with state law, accreditation standards, and OTP licensing requirements should be assessed prior to adoption. Although SAMHSA’s 2023 Harm Reduction Framework provides important federal support for risk reduction approaches in the care of people who use drugs, variability in interpretation and adoption may persist across programs. ¹⁷ Additional limitations include potential institutional stigma, particularly in abstinence-oriented treatment settings, which may influence both staff willingness to offer and patient willingness to access kits or disclose ongoing substance use. Resource constraints, including limited staffing capacity and lack of reimbursement for risk reduction services, may further impact implementation in other OTPs. Kit uptake does not necessarily reflect use of the supplies, and whether kits were used as intended is unknown. The qualitative findings were based on open-ended responses from a small sample, limiting generalizability; future studies should formally assess staff acceptability and perceived impact. Finally, although kit distribution was supported through the clinic budget at this site long-term sustainability will require dedicated funding and program considering adoption should identify potential grant sources, health department partnerships to support implementation.

Conclusions

There remains an urgent need to strengthen efforts aimed at reducing drug use-related morbidity and mortality, particularly amid unprecedented rates of overdose deaths and rising infectious complications associated with substance use. In response, OTPs should consider integrating safer use kits and other risk reduction services as a standard component of care. Doing so is feasible and demonstrates early promise for improving patient engagement and staff–patient relationships; however, future study is needed for downstream effects on retention, safety, and clinical outcomes.